ETHZilla

ETHZilla Liabilities

The The Liabilities of ETHZilla (ETHZ) as of Oct 27, 2026 is 66.88 B USD. In the previous year, The Liabilities was 3.51 M USD — a change of 1.90 M% (higher).

Liabilities

66.88 BUSD

YoY

1.90 M%

Last updated:

In 2025, ETHZilla's total liabilities amounted to 66.88 B USD, a 1.90 M% difference from the 3.51 M USD total liabilities in the previous year.

The ETHZilla Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
9.14 M USD
Jan 1, 2019
13.31 M USD
Jan 1, 2020
25.25 M USD
Jan 1, 2021
23.39 M USD
Jan 1, 2022
8.31 M USD
Jan 1, 2023
5.39 M USD
Jan 1, 2024
3.51 M USD
Jan 1, 2025
66.88 B USD
The ETHZilla Liabilities history
YEARLiabilitiesYoY
66.88 BUSD+1.90 M%
3.51 MUSD-34.82%
5.39 MUSD-35.14%
8.31 MUSD-64.49%
23.39 MUSD-7.35%
25.25 MUSD+89.63%
13.31 MUSD+45.72%
9.14 MUSD+115.83%
4.23 MUSD+1,841.80%
218,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ETHZilla Stock analysis

What does ETHZilla do? 180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases, focusing on three research programs: Fibrosis and Anti-TNF, SCAs, and a7nAChR. The Fibrosis and Anti-TNF program targets conditions such as Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), and nonalcoholic steatohepatitis (NASH). The SCAs program addresses chronic pain and early arthritis, while the a7nAChR program focuses on smoking cessation and ulcerative colitis. The company generates revenue through the development and potential future sale of these pharmaceutical products, targeting patients and healthcare providers in the treatment of inflammatory and chronic pain conditions. The company operates as a research and development firm with a pipeline of drugs in separate areas of inflammation. Its products are designed to treat specific diseases within inflammation, including Dupuytren’s contracture, frozen shoulder, POCD, NASH, chronic pain, early arthritis, and ulcerative colitis. Revenue is derived from the commercialization of these pharmaceuticals once they reach the market, with no mention of current sales or partnerships in the business description. 180 Life Sciences Corp. is structured around three distinct drug development programs, each targeting a specific disease area. The Fibrosis and Anti-TNF program covers multiple inflammatory conditions, while SCAs and a7nAChR address chronic pain and smoking-related health issues, respectively. The company’s revenue model relies on the successful development and market entry of these pharmaceuticals, with no indication of current revenue streams beyond its R&D phase. ETHZilla is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing ETHZilla's Liabilities

ETHZilla's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ETHZilla's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing ETHZilla's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

ETHZilla's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in ETHZilla’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about ETHZilla stock

The Liabilities of ETHZilla is 66.88 B USD in 2025.

The Liabilities of ETHZilla changed from 3.51 M USD to 66.88 B USD, representing a 1.90 M% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities ETHZilla since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's ETHZilla historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ETHZilla

All Key Metrics — ETHZilla